Correction to: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression (Nature Medicine, (2016), 22, 5, (497-505), 10.1038/nm.4082);Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression

Nature Medicine

Volumn 22, Issue 5, 2016, Pages 497-505

  Laklai, Hanane ^a   Miroshnikova, Yekaterina A ^a   Pickup, Michael W ^a   Collisson, Eric A ^a   Kim, Grace E ^a   Barrett, Alex S ^b   Hill, Ryan C ^b   Lakins, Johnathon N ^a   Schlaepfer, David D ^c   Mouw, Janna K ^a   LeBleu, Valerie S ^d   Roy, Nilotpal ^a   Novitskiy, Sergey V ^e   Johansen, Julia S ^f   Poli, Valeria ^g   Kalluri, Raghu ^d   Iacobuzio Donahue, Christine A ^h   Wood, Laura D ⁱ   Hebrok, Matthias ^a   Hansen, Kirk ^b   Moses, Harold L ^e   Weaver, Valerie M ^a,j,k   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY OF TURIN   (Italy)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA1 INTEGRIN; COLLAGEN GEL; COLLAGEN TYPE 12; COLLAGEN TYPE 3; FIBRILLAR COLLAGEN; FIBRONECTIN; JANUS KINASE; K RAS PROTEIN; MYOSIN ADENOSINE TRIPHOSPHATASE; MYOSIN LIGHT CHAIN 2; RUXOLITINIB; SHORT HAIRPIN RNA; SMAD2 PROTEIN; SMAD4 PROTEIN; STAT3 PROTEIN; TENASCIN; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; VIMENTIN; BETA INTEGRIN; COLLAGEN; KRAS2 PROTEIN, MOUSE; PROTEIN P21; SMAD4 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER GROWTH; CHRONIC PANCREATITIS; COLLAGEN FIBER; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; EXTRACELLULAR MATRIX; FEMALE; FIBROSIS; FOCAL ADHESION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MATRICELLULAR FIBROSIS; MECHANOTRANSDUCTION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHENOTYPE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR BIOPSY; ANIMAL; DISEASE COURSE; DISEASE MODEL; GENETICS; LIQUID CHROMATOGRAPHY; METABOLISM; MORTALITY; MUTATION; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CHROMATOGRAPHY, LIQUID; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FIBROSIS; GENOTYPE; HUMANS; INTEGRIN BETA CHAINS; MICE; MICROSCOPY, ATOMIC FORCE; MUTATION; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEOMICS; PROTO-ONCOGENE PROTEINS P21(RAS); REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; STAT3 TRANSCRIPTION FACTOR; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; TRANSFORMING GROWTH FACTOR BETA; TUMOR MICROENVIRONMENT;

EID: 84964317478     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-023-02694-w     Document Type: Erratum

References (69)

1. Chauhan, V.P. et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516 (2013).
2. Swartz, M.A. & Lund, A.W. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat. Rev. Cancer 12, 210-219 (2012).
3. Yu, M. & Tannock, I.F. Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell 21, 327-329 (2012).
4. Provenzano, P.P. & Hingorani, S.R. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br. J. Cancer 108, 1-8 (2013).
5. Olive, K.P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
6. Provenzano, P.P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429 (2012).
7. Rosow, D.E. et al. Sonic Hedgehog in pancreatic cancer: from bench to bedside, then back to the bench. Surgery 152 (suppl. 1), S19-S32 (2012).
8. Özdemir, B.C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719-734 (2014).
9. Rhim, A.D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735-747 (2014).
10. Jain, R.K., Martin, J.D. & Stylianopoulos, T. The role of mechanical forces in tumor growth and therapy. Annu. Rev. Biomed. Eng. 16, 321-346 (2014).
11. Neesse, A. et al. Stromal biology and therapy in pancreatic cancer. Gut 60, 861-868 (2011).
12. Stromnes, I.M., DelGiorno, K.E., Greenberg, P.D. & Hingorani, S.R. Stromal reengineering to treat pancreas cancer. Carcinogenesis 35, 1451-1460 (2014).
13. Cheung, K.J., Gabrielson, E., Werb, Z. & Ewald, A.J. Collective invasion in breast cancer requires a conserved basal epithelial program. Cell 155, 1639-1651 (2013).
14. Hoadley, K.A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929-944 (2014).
15. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
16. Sugimoto, H., Mundel, T.M., Kieran, M.W. & Kalluri, R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol. Ther. 5, 1640-1646 (2006).
17. Wang, Y., You, M. & Wang, Y. Alternative splicing of the K-ras gene in mouse tissues and cell lines. Exp. Lung Res. 27, 255-267 (2001).
18. Paszek, M.J. et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 8, 241-254 (2005).
19. Samuel, M.S. et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and β-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 19, 776-791 (2011).
20. Iacobuzio-Donahue, C.A. et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J. Clin. Oncol. 27, 1806-1813 (2009).
21. Whittle, M.C. et al. RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell 161, 1345-1360 (2015).
22. Ijichi, H. et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-β signaling in cooperation with active Kras expression. Genes Dev. 20, 3147-3160 (2006).
23. Collisson, E.A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503 (2011).
24. Moffitt, R.A. et al. Virtual microdissection identifies distinct tumor- and stromaspecific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168-1178 (2015).
25. Kabashima, A. et al. Side population of pancreatic cancer cells predominates in TGF-β-mediated epithelial to mesenchymal transition and invasion. Int. J. Cancer 124, 2771-2779 (2009).
26. Dangi-Garimella, S. et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 71, 1019-1028 (2011).
27. Erkan, M. et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6, 1155-1161 (2008).
28. Sinn, M. et al. α-smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Br. J. Cancer 111, 1917-1923 (2014).
29. Bever, K.M. et al. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB 17, 292-298 (2015).
30. Wang, W.Q. et al. Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer. PLoS One 8, e71189 (2013).
31. Rath, N. & Olson, M.F. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep. 13, 900-908 (2012).
32. Schultz, N.A. et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod. Pathol. 25, 1609-1622 (2012).
33. Pérez-Mancera, P.A., Guerra, C., Barbacid, M. & Tuveson, D.A. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142, 1079-1092 (2012).
34. Macias, M.J., Martin-Malpartida, P. & Massagué, J. Structural determinants of Smad function in TGF-β signaling. Trends Biochem. Sci. 40, 296-308 (2015).
35. Shi, Y. & Massagué, J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
36. Yachida, S. et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin. Cancer Res. 18, 6339-6347 (2012).
37. Hingorani, S.R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
38. G12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
39. Dupont, S. et al. Role of YAP/TAZ in mechanotransduction. Nature 474, 179-183 (2011).
40. Blackford, A. et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin. Cancer Res. 15, 4674-4679 (2009).
41. Sanz-Moreno, V. et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 20, 229-245 (2011).
42. Fukuda, A. et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 19, 441-455 (2011).
43. Lesina, M. et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19, 456-469 (2011).
44. Nagathihalli, N.S. et al. Signal transducer and activator of transcription 3, mediated remodeling of the tumor microenvironment results in enhanced tumor drug delivery in a mouse model of pancreatic cancer. Gastroenterology 149, 1932-1943 (2015).
45. Ijichi, H. et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J. Clin. Invest. 121, 4106-4117 (2011).
46. Schrader, J. et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology 53, 1192-1205 (2011).
47. Mouw, J.K. et al. Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat. Med. 20, 360-367 (2014).
48. Li, R. et al. Activation of integrin αIIbβ3 by modulation of transmembrane helix associations. Science 300, 795-798 (2003).
49. Barbieri, I. et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res. 70, 2558-2567 (2010).
50. Alonzi, T. et al. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation in the liver. Mol. Cell. Biol. 21, 1621-1632 (2001).
51. Luna, A. et al. Multiparametric MR imaging in abdominal malignancies. Magn. Reson. Imaging Clin. N. Am. 24, 157-186 (2016).
52. Chauhan, V.P. et al. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell 26, 14-15 (2014).
53. Herreros-Villanueva, M. et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2, e61 (2013).
54. Shao, D.D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171-184 (2014).
55. Jiang, J. et al. MiR-1181 inhibits stem cell-like phenotypes and suppresses SOX2 and STAT3 in human pancreatic cancer. Cancer Lett. 3562 Pt B, 962-970 (2015).
56. Yimlamai, D. et al. Hippo pathway activity influences liver cell fate. Cell 157, 1324-1338 (2014).
57. Kohler, I. et al. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma. J. Gastroenterol. Hepatol. 30 (suppl. 1), 78-84 (2015).
58. Paron, I. et al. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS ONE 6, e21684 (2011).
59. Esposito, I. et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J. Pathol. 208, 673-685 (2006).
60. Hill, R.C., Calle, E.A., Dzieciatkowska, M., Niklason, L.E. & Hansen, K.C. Quantification of extracellular matrix proteins from a rat lung scaffold to provide a molecular readout for tissue engineering. Mol. Cell. Proteomics 14, 961-973 (2015).
61. Lopez, J.I., Kang, I., You, W.-K., McDonald, D.M. & Weaver, V.M. In situ force mapping of mammary gland transformation. Integr. Biol. (Camb) 3, 910-921 (2011).
62. Pickup, M.W. et al. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas. Cancer Res. 73, 5336-5346 (2013).
63. Bullen, A., Friedman, R.S. & Krummel, M.F. Two-photon imaging of the immune system: a custom technology platform for high-speed, multicolor tissue imaging of immune responses. Curr. Top. Microbiol. Immunol. 334, 1-29 (2009).
64. Aguirre, A.J. et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17, 3112-3126 (2003).
65. Damiano, L. et al. Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin. Oncogene 33, 2441-2453 (2014).
66. Reinhart-King, C.A., Dembo, M. & Hammer, D.A. Endothelial cell traction forces on RGD-derivatized polyacrylamide substrata. Langmuir 19, 1573-1579 (2003).
67. Lakins, J.N., Chin, A.R. & Weaver, V.M. Methods Mol. Biol. 916, 317-350 (2012).
68. Paszek, M.J. et al. The cancer glycocalyx mechanically primes integrin-mediated growth and survival. Nature 511, 319-325 (2014).
69. Mann, M.D., Crouse, D.A. & Prentice, E.D. Appropriate animal numbers in biomedical research in light of animal welfare considerations. Lab. Animal Sci. 41, 6-14 (1991).